Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Appili Therapeutics Inc APLIF


Primary Symbol: T.APLI

Healthcare
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical... see more

Bullboard (TSX:APLI)

View:
1 2 3 4 5 6 Next
Comment by MrBinkson Aug 18, 2024 12:04am

RE:New shareholder.

I'm curious. Do you still think this one will gain value in the near future?
27
Discussion
Post by Betteryear2on Apr 02, 2024 10:08am

Appili Therapeutics Sign Definitive Agreement to be Acquired

Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR ...more  
273
Post by BradlTheGermanon Dec 17, 2023 2:29am

ATI -1701

Appili was granted a pre-IND meeting with the FDA to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies and expects to receive feedback in early 2024. The goal of the ATI-1701 ...more  
306
Post by BradlTheGermanon Dec 16, 2023 3:45pm

New shareholder.

I have bought my first 75.000 shares over the last two weeks. I am going to double or triple my position over the next year. I will hold my shares until 2028. I am sure for 150 percent  that I ...more  
319
Discussion
Post by mba123ccuon Sep 25, 2023 8:57am

FDA approval for ATI-1501

Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral Suspension Very important milestone achieved......looking forward to more of this positive news in the near ...more  
267
Post by RJSullivanon Jul 17, 2023 3:01pm

Seems severely under-valued. Big potential

This stock looks to have been severely punished in the past and perhaps folks are starting to look at their pipeline and realize that it's severely undervalued. Being able to combat anaerobic ...more  
334
Post by opsd1on Nov 15, 2022 10:14am

APLI Secures US$14 million from US DoD for Biodefense

Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy https://stockhouse.com/news/press ...more  
231
Discussion
Post by bmreedon Apr 14, 2022 3:47pm

News Update w Radius Research and $APLI CEO Armand Balboni

News Update: Appili Therapeutics (APLI) w CEO Dr. Armand Balboni  - Develop Leishmaniasis Treatment ATI-1801 - https://www.youtube.com/watch?v=YyE8zLvWApM {^youtubevideo|(width)425 ...more  
277
Post by ecanadian2on Apr 12, 2022 8:25pm

yes, lots of potential and appears to be a well run

company but: * $3.6M they raised will be used almost in full to pay off the previous loan * the interest on the new loan will be at least $1/4 million a year ... and APLI has precious little money on ...more  
404
Post by bmreedon Apr 11, 2022 10:32am

Webinar Recap w Radius Research & $APLI CEO Armand Balboni

Webinar Recap: Appili Therapeutics (APLI) w CEO Dr. Armand Balboni - Drug Development Focused on Infectious Diseases - Pitch, Deep Dive, and Q&A - https://www.youtube.com/watch?v=xGrmHACzU7c  ...more  
224
Post by bmreedon Apr 04, 2022 10:25am

Webinar w $APLI CEO Armand Balboni Fri Apr 8 @ 12:30PM ET

Webinar - Appili Therapeutics (APLI) w/ CEO Dr. Armand Balboni Fri, Apr 8 at 12:30pm ET / 9:30am PT Q&A with Radius Research  Register Here - https://us02web.zoom.us/webinar ...more  
147
Post by Betteryear2on Mar 29, 2022 2:23pm

Appili Therapeutics Announces Non-Convertible Secured Loan

March 29, 2022 07:36 AM Eastern Daylight Time HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company ...more  
170
Post by ecanadian2on Mar 16, 2022 12:37am

Will Lind be converting $3 mil into shares after Mar 18?!!

Will Lind be converting $3 million into shares after Friday March 18?! That would be 10s of millions of shares unloaded on the illiquid APLI market. Scary ... still no update from APLI on this. " ...more  
192
Post by Betteryear2on Feb 28, 2022 7:58am

Over US$10 M in New Funding from US Department of Defense

February 28, 2022 07:40 AM Eastern Standard Time HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical ...more  
183
1 2 3 4 5 6 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities